Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CareDx ( (CDNA) ) has issued an update.
CareDx announced the appointment of Nathan Smith as the new Chief Financial Officer effective August 7, 2025, following the retirement of Abhishek Jain. The company also reported its second quarter 2025 financial results, highlighting a 14% year-over-year increase in adjusted revenue to $90.5 million and a narrowed full-year revenue guidance to $367 million to $373 million. CareDx continues to strengthen its position in the transplant care industry with significant growth in testing services and the launch of new products.
The most recent analyst rating on (CDNA) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on CareDx stock, see the CDNA Stock Forecast page.
Spark’s Take on CDNA Stock
According to Spark, TipRanks’ AI Analyst, CDNA is a Neutral.
CareDx’s strong financial performance and positive earnings outlook are significant strengths, supported by a robust balance sheet and strategic initiatives like stock repurchases. However, the current technical indicators point to bearish market sentiment, which tempers the overall score.
To see Spark’s full report on CDNA stock, click here.
More about CareDx
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients.
Average Trading Volume: 1,511,533
Technical Sentiment Signal: Sell
Current Market Cap: $715.5M
For an in-depth examination of CDNA stock, go to TipRanks’ Overview page.